Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15804441 | 0.80 | APLNR (0.33) | SMN1; SMN2LMNABLMPMP22APLNR | |
| SCHEMBL5532753 | 0.78 | APLNR (0.48) | SMN1; SMN2LMNAALOX15BLMPMP22 | |
| SCHEMBL26965811 | 0.77 | APLNR (0.38) | GAASMN1; SMN2LMNAALOX15TDP1 | |
| SCHEMBL26535538 | 0.76 | APLNR (0.31) | APLNRMAPT | |
| SCHEMBL21293559 | 0.76 | CA2 (0.33) | CA2 | |
| SCHEMBL30237791 | 0.74 | CHRNB2 (0.34) | SMN1; SMN2LMNABLMPMP22APLNR | |
| Lithium Ion SCHEMBL28600847 | 0.74 | CA1 (0.30) | APLNR | |
| SCHEMBL31250265 | 0.74 | GRM2 (0.33) | GAASMN1; SMN2LMNAALOX15TDP1 | |
| SCHEMBL12699542 | 0.73 | DPP4 (0.31) | — | |
| SCHEMBL15742160 | 0.73 | GAA (0.38) | GAACA2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0643055-B1 | Proces for the preparation of 5-amino-2,2-dialkyl-1,3-dioxanes | ZAMBON SPA (IT) | 1997-10-08 | — | — | EP | claimed |
| US-5580993-A | Process for the preparation of iopamidol and 5-amino-2,2-dialkyl-1,3-dioxanes | ZAMBON GROUP S.P.A. (IT) | 1996-12-03 | — | — | US | claimed |
| EP-0643055-A1 | Proces for the preparation of 5-amino-2,2-dialkyl-1,3-dioxanes | ZAMBON GROUP S.p.A. (IT) | 1995-03-15 | — | — | EP | claimed |
| JP-7149755-A | — | — | None | — | — | JP | disclosed |
| US-20150148543-A1 | Methods and Compositions for the Synthesis of Multimerizing Agents | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-28 | — | — | US | disclosed |
| US-9024028-B2 | Methods and compositions for the synthesis of multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140171649-A1 | Methods and Compositions for the Synthesis of Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2012103279-A2 | METHODS AND COMPOSITIONS FOR THE SYNTHESIS OF MULTIMERIZING AGENTS | ARIAD PHARMACEUTICALS, INCORPORATED (US) | 2012-08-02 | — | — | WO | disclosed |
| US-20090076062-A1 | Organic Compounds | MAIBAUM JUERGEN KLAUS | 2009-03-19 | — | — | US | disclosed |
| EP-0643055-B1 | Proces for the preparation of 5-amino-2,2-dialkyl-1,3-dioxanes | ZAMBON SPA (IT) | 1997-10-08 | — | — | EP | disclosed |
| US-5580993-A | Process for the preparation of iopamidol and 5-amino-2,2-dialkyl-1,3-dioxanes | ZAMBON GROUP S.P.A. (IT) | 1996-12-03 | — | — | US | disclosed |
| JP-H07149755-A | PREPARATION OF 5-AMINO-2,2-DIALKYL-1,3-DIOXANE | ZAMBON GROUP SPA | 1995-06-13 | — | — | JP | disclosed |
| EP-0643055-A1 | Proces for the preparation of 5-amino-2,2-dialkyl-1,3-dioxanes | ZAMBON GROUP S.p.A. (IT) | 1995-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171649-A1 | Methods and Compositions for the Synthesis of Multimerizing Agents | PIP5K1C, PIP4K2C, IPMK | GAA 4258/4885SMN1; SMN2 3123/4885LMNA 2257/4885 |
| US-20150148543-A1 | Methods and Compositions for the Synthesis of Multimerizing Agents | PARG, POLI, MCM6 | GAA 1490/4885SMN1; SMN2 2241/4885LMNA 828/4885 |
| US-20090076062-A1 | Organic Compounds | AGTR1, AGTR2, REN | GAA 322/4885SMN1; SMN2 2362/4885LMNA 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.